On the February
- Surface expression, function, and pharmacology of disease-associated mutations in human NMDA receptors – molecular diagnostics and drug development
- Targeted treatment for protein mutation and aggregation diseases – tauopathies, amyloidosis and cancer
- Targeted therapy for cells in stress – regulators of oncogenic, ribosomal and/or endoplasmatic stress response
- Gene expression therapeutics – epigenetic and transcriptional regulators
- Novel potent inhibitors of purine nucleoside phosphorylase for treatment of T-cell
leukemia Senolytics – cytotoxic therapies foraging cells- New human Constitutive androstane receptor (CAR, NR1I3) ligands for the treatment of metabolic diseases